ACADIA Pharmaceuticals Inc
$ 27.62
-0.90%
26 Dec - close price
- Market Cap 4,672,802,000 USD
- Current Price $ 27.62
- High / Low $ 27.95 / 27.40
- Stock P/E 17.82
- Book Value 5.42
- EPS 1.55
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.35 %
- 52 Week High 28.35
- 52 Week Low 13.40
About
ACADIA Pharmaceuticals Inc., based in San Diego, California, is a prominent biopharmaceutical company specializing in the development and commercialization of innovative therapies targeting central nervous system disorders. The company has a robust pipeline of small molecule drugs with a significant focus on addressing unmet medical needs in conditions such as Parkinson's disease psychosis and schizophrenia. ACADIA’s commitment to scientific innovation, coupled with strategic partnerships, strengthens its competitive position in the healthcare sector and underscores its mission to enhance patient outcomes while driving sustainable growth.
Analyst Target Price
$29.79
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-02 | 2023-05-08 | 2023-02-27 |
| Reported EPS | 0.42 | 0.16 | 0.11 | 0.86 | 0.2 | 0.2 | 0.1 | 0.28 | -0.4 | 0.01 | -0.27 | -0.26 |
| Estimated EPS | 0.1438 | 0.14 | 0.05 | 0.219 | 0.14 | 0.18 | 0.05 | 0.3 | -0.43 | -0.08 | -0.21 | -0.24 |
| Surprise | 0.2762 | 0.02 | 0.06 | 0.641 | 0.06 | 0.02 | 0.05 | -0.02 | 0.03 | 0.09 | -0.06 | -0.02 |
| Surprise Percentage | 192.0723% | 14.2857% | 120% | 292.6941% | 42.8571% | 11.1111% | 100% | -6.6667% | 6.9767% | 112.5% | -28.5714% | -8.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACAD
2025-12-27 12:08:38
Rice Hall James & Associates LLC has reduced its stake in ACADIA Pharmaceuticals Inc. by selling 54,869 shares, now holding 614,937 shares valued at approximately $13.12 million. This sale represents an 8.2% decrease in their position. Insider transactions also show sales totaling over $1 million, though institutions largely maintain high ownership with a "Moderate Buy" consensus from analysts.
2025-12-23 03:08:47
Acadia Pharmaceuticals stock aggressively rose to a 52-week high of $27.73, marking a 61% increase over the past year and reflecting strong investor confidence. The company's financial health is rated "GREAT" with a robust current ratio of 3.02, and it appears undervalued despite its strong performance. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to its positive outlook.
2025-12-22 20:09:25
Acadia Pharmaceuticals Inc. (ACAD) has achieved a 52-week high of $27.73, representing a 61% increase over the past year. This milestone is supported by the company's "GREAT" financial health score of 3.64 and a robust current ratio of 3.02, reflecting strong investor confidence and solid market performance. Recent developments include FDA approval for DAYBUE STIX and varied analyst price target adjustments, generally indicating a positive outlook.
2025-12-22 16:09:59
Acadia Pharmaceuticals stock has reached a 52-week high of $27.73, reflecting a 61% increase over the past year and strong investor confidence. The company maintains a "GREAT" financial health score and its stock appears undervalued at its current price. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to a positive outlook for the biopharmaceutical firm.
2025-12-21 21:09:59
ACADIA Pharmaceuticals (ACAD) has seen significant growth in its share price over the past year, up 61%, and is currently trading just below consensus price targets. Despite this rally, a detailed long-term cash flow analysis suggests the stock might be modestly undervalued, with a narrative fair value of $29.32 against a current price of $27.16. The valuation hinges on assumptions of durable double-digit growth and steady margins, and investors should consider potential risks like NUPLAZID’s concentration risk or setbacks in late-stage trials.
2025-12-18 21:07:53
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco. Catherine Owen Adams, CEO, will represent the company, and a live webcast will be available on acadia.com. The company also highlighted its commitment to neurological and rare disease communities, with FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and a robust pipeline.
